Compare HAL & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAL | KVUE |
|---|---|---|
| Founded | 1919 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Specialty Chemicals |
| Sector | Energy | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9B | 32.9B |
| IPO Year | 2006 | 2023 |
| Metric | HAL | KVUE |
|---|---|---|
| Price | $40.72 | $17.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 11 |
| Target Price | ★ $38.61 | $19.45 |
| AVG Volume (30 Days) | 9.4M | ★ 19.5M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | 1.63% | ★ 4.82% |
| EPS Growth | N/A | ★ 40.74 |
| EPS | ★ 0.55 | 0.25 |
| Revenue | ★ $17,973,000,000.00 | $15,124,000,000.00 |
| Revenue This Year | N/A | $4.85 |
| Revenue Next Year | $4.19 | $2.63 |
| P/E Ratio | $74.60 | ★ $67.40 |
| Revenue Growth | ★ 22.47 | N/A |
| 52 Week Low | $20.09 | $14.02 |
| 52 Week High | $43.59 | $22.87 |
| Indicator | HAL | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 51.97 | 43.91 |
| Support Level | $33.20 | $16.89 |
| Resistance Level | $41.18 | $17.20 |
| Average True Range (ATR) | 1.09 | 0.32 |
| MACD | -0.20 | -0.04 |
| Stochastic Oscillator | 42.90 | 21.39 |
Halliburton is North America's largest oilfield-services company as measured by market share. Despite industry fragmentation, it holds a leading position in the hydraulic fracturing and completions market, which makes up nearly half of its revenue. It also holds strong positions in other service offerings like drilling and completions fluids, which leverages its expertise in material science, as well as the directional drilling market. While we consider SLB the global leader in reservoir evaluation, we think Halliburton leads in any activity from the reservoir to the wellbore. Halliburton's innovations have helped multiple producers lower their development costs per barrel of oil equivalent, with techniques that have been honed over a century of operations.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.